Emicizumab Safe, Effective, in Infants With Hemophilia A
SAN DIEGO — Administering emicizumab (Hemlibra) to previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors is effective and safe, according to results from research presented here. The phase III HAVEN-7 study showed that at a median follow-up of 101.9 weeks, the annualized treated bleeding rate was 0.4 (95% CI […]
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A
Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of immunosuppressive therapy in this vulnerable population, a phase II study showed. Over 12 weeks of therapy, a high-dose regimen of the factor VIIIa mimetic antibody yielded a low mean breakthrough bleeding rate […]